Waagstein F
Wallenberg Laboratory, Department of Medicine I, University of Göteborg, Sahlgren's Hospital, Sweden.
Heart Vessels Suppl. 1991;6:18-28. doi: 10.1007/BF01752532.
Beta-blockers were initially given to patients with chronic heart failure due to ischemic heart disease and resting tachycardia. The prompt effect on severe backward heart failure was directly associated with an immediate fall in heart rate. This observation led to long-term administration to patients with idiopathic dilated cardiomyopathy and, later, to patients with ischemic cardiomyopathy and secondary cardiomyopathies as well. Due to marked down-regulation of beta receptors, patients with heart failure are extremely sensitive to beta blockade. A test dose of metoprolol 5 mg b.i.d. for 2 days is recommended to select patients for long-term beta-blockade, followed by careful titration with increment in dose over 6 weeks. One important effect of beta-blockade in the early phase of treatment is a reduction in the myocardial energy demand early after the onset of long-term treatment. After 1 month of treatment with beta-blockers, marked improvement of diastolic function is observed. This effect might be attributed to inhibition of calcium overload. After 3 months of treatment, an increase in ejection fraction can be observed, which might be attributed to upregulation of beta receptors. The withdrawal of long-term treatment was followed by a deterioration of heart function in 61% of patients and improvement was seen after reinstitution of beta-blockade. There was an increase in cardiac index and stroke work index at rest as well as during supine exercise. A marked fall in left ventricular filling pressure at rest and unchanged filling pressure during supine exercise was noted, while exercise capacity increased by 25%. A similar pattern was seen in patients with ischemic cardiomyopathies and other secondary cardiomyopathies. However, the increase in ejection fraction in the ischemic cardiomyopathy group was lower (0.06) compared to the groups with dilated cardiomyopathy and other secondary cardiomyopathies (0.18).
β受体阻滞剂最初用于患有缺血性心脏病和静息性心动过速的慢性心力衰竭患者。其对严重的失代偿性心力衰竭的迅速疗效与心率立即下降直接相关。这一观察结果使得β受体阻滞剂开始长期应用于特发性扩张型心肌病患者,随后也应用于缺血性心肌病和继发性心肌病患者。由于心力衰竭患者的β受体显著下调,他们对β受体阻滞极为敏感。建议给予患者美托洛尔试验剂量5mg,每日两次,持续2天,以选择适合长期β受体阻滞治疗的患者,随后在6周内仔细滴定增加剂量。β受体阻滞在治疗早期的一个重要作用是在长期治疗开始后早期降低心肌能量需求。在用β受体阻滞剂治疗1个月后,可观察到舒张功能显著改善。这种作用可能归因于对钙超载的抑制。治疗3个月后,可观察到射血分数增加,这可能归因于β受体上调。在61%的患者中,长期治疗停药后心功能恶化,重新使用β受体阻滞剂后心功能改善。静息时以及仰卧运动时心脏指数和每搏功指数均增加。静息时左心室充盈压显著下降,仰卧运动时充盈压无变化,同时运动能力提高了25%。缺血性心肌病和其他继发性心肌病患者也出现类似情况。然而,与扩张型心肌病和其他继发性心肌病组相比,缺血性心肌病组射血分数的增加较低(0.06)。